vs

Side-by-side financial comparison of Anterix Inc. (ATEX) and Wellgistics Health, Inc. (WGRX). Click either name above to swap in a different company.

Wellgistics Health, Inc. is the larger business by last-quarter revenue ($1.7M vs $1.6M, roughly 1.1× Anterix Inc.). Anterix Inc. runs the higher net margin — -419.6% vs -1667.2%, a 1247.6% gap on every dollar of revenue.

Anterix Inc. is a U.S.-headquartered wireless communications company that owns licensed 900 MHz spectrum assets, providing secure, dedicated private broadband network solutions for critical infrastructure operators including electric utilities, public safety agencies, and transportation providers. Its primary market is North America, supporting clients requiring highly reliable connectivity for mission-critical operations.

Wellgistics Health, Inc. is a U.S.-headquartered healthcare services firm focused on the distribution of prescription pharmaceuticals, over-the-counter medications, and medical supplies. Its key customer segments include retail pharmacies, long-term care facilities, and independent healthcare providers across the domestic market.

ATEX vs WGRX — Head-to-Head

Bigger by revenue
WGRX
WGRX
1.1× larger
WGRX
$1.7M
$1.6M
ATEX
Higher net margin
ATEX
ATEX
1247.6% more per $
ATEX
-419.6%
-1667.2%
WGRX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ATEX
ATEX
WGRX
WGRX
Revenue
$1.6M
$1.7M
Net Profit
$-6.6M
$-27.9M
Gross Margin
-470.2%
Operating Margin
-576.0%
-1517.5%
Net Margin
-419.6%
-1667.2%
Revenue YoY
0.4%
Net Profit YoY
-185.6%
EPS (diluted)
$-0.35
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATEX
ATEX
WGRX
WGRX
Q4 25
$1.6M
$1.7M
Q3 25
$1.6M
$3.0M
Q2 25
$1.4M
$7.8M
Q1 25
$1.4M
$10.9M
Q4 24
$1.6M
Q3 24
$1.6M
Q2 24
$1.5M
Q1 24
$1.3M
Net Profit
ATEX
ATEX
WGRX
WGRX
Q4 25
$-6.6M
$-27.9M
Q3 25
$53.5M
$-34.3M
Q2 25
$25.2M
$-6.7M
Q1 25
$9.2M
$-32.4M
Q4 24
$7.7M
Q3 24
$-12.8M
Q2 24
$-15.5M
Q1 24
$-9.4M
Gross Margin
ATEX
ATEX
WGRX
WGRX
Q4 25
-470.2%
Q3 25
7.7%
Q2 25
6.5%
Q1 25
6.4%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ATEX
ATEX
WGRX
WGRX
Q4 25
-576.0%
-1517.5%
Q3 25
-1047.1%
Q2 25
-70.6%
Q1 25
-288.6%
Q4 24
Q3 24
-846.6%
Q2 24
-984.4%
Q1 24
-834.2%
Net Margin
ATEX
ATEX
WGRX
WGRX
Q4 25
-419.6%
-1667.2%
Q3 25
3449.5%
-1139.0%
Q2 25
1775.7%
-85.6%
Q1 25
662.9%
-298.5%
Q4 24
492.3%
Q3 24
-823.1%
Q2 24
-1018.0%
Q1 24
-746.9%
EPS (diluted)
ATEX
ATEX
WGRX
WGRX
Q4 25
$-0.35
$-0.24
Q3 25
$2.86
$-0.46
Q2 25
$1.35
$-0.11
Q1 25
$0.51
$-0.62
Q4 24
$0.41
Q3 24
$-0.69
Q2 24
$-0.84
Q1 24
$-0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATEX
ATEX
WGRX
WGRX
Cash + ST InvestmentsLiquidity on hand
$29.5M
$42.6K
Total DebtLower is stronger
$23.5M
Stockholders' EquityBook value
$236.0M
$-12.4M
Total Assets
$417.0M
$30.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATEX
ATEX
WGRX
WGRX
Q4 25
$29.5M
$42.6K
Q3 25
$39.1M
$4.2M
Q2 25
$41.4M
$419.9K
Q1 25
$47.4M
$2.5M
Q4 24
$28.8M
Q3 24
$43.1M
Q2 24
$51.7M
Q1 24
$60.6M
Total Debt
ATEX
ATEX
WGRX
WGRX
Q4 25
$23.5M
Q3 25
$24.8M
Q2 25
$23.3M
Q1 25
$24.1M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ATEX
ATEX
WGRX
WGRX
Q4 25
$236.0M
$-12.4M
Q3 25
$240.3M
$6.8M
Q2 25
$184.8M
$905.3K
Q1 25
$156.6M
$4.5M
Q4 24
$144.7M
Q3 24
$139.1M
Q2 24
$148.8M
Q1 24
$161.0M
Total Assets
ATEX
ATEX
WGRX
WGRX
Q4 25
$417.0M
$30.5M
Q3 25
$420.4M
$52.8M
Q2 25
$359.6M
$54.2M
Q1 25
$333.1M
$58.1M
Q4 24
$326.7M
Q3 24
$317.2M
Q2 24
$321.1M
Q1 24
$324.9M
Debt / Equity
ATEX
ATEX
WGRX
WGRX
Q4 25
Q3 25
3.66×
Q2 25
25.72×
Q1 25
5.39×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATEX
ATEX
WGRX
WGRX
Operating Cash FlowLast quarter
$-8.3M
$-6.3M
Free Cash FlowOCF − Capex
$-8.3M
FCF MarginFCF / Revenue
-526.4%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATEX
ATEX
WGRX
WGRX
Q4 25
$-8.3M
$-6.3M
Q3 25
$1.4M
$-1.1M
Q2 25
$-3.1M
$-2.1M
Q1 25
$-16.6M
$-1.3M
Q4 24
$-7.7M
Q3 24
$-2.6M
Q2 24
$-2.4M
Q1 24
$6.1M
Free Cash Flow
ATEX
ATEX
WGRX
WGRX
Q4 25
$-8.3M
Q3 25
Q2 25
Q1 25
$-16.6M
Q4 24
Q3 24
$-2.7M
Q2 24
Q1 24
$6.1M
FCF Margin
ATEX
ATEX
WGRX
WGRX
Q4 25
-526.4%
Q3 25
Q2 25
Q1 25
-1195.2%
Q4 24
Q3 24
-173.4%
Q2 24
Q1 24
484.1%
Capex Intensity
ATEX
ATEX
WGRX
WGRX
Q4 25
0.6%
Q3 25
Q2 25
Q1 25
3.3%
Q4 24
0.0%
Q3 24
2.6%
Q2 24
0.0%
Q1 24
3.2%
Cash Conversion
ATEX
ATEX
WGRX
WGRX
Q4 25
Q3 25
0.03×
Q2 25
-0.12×
Q1 25
-1.80×
Q4 24
-1.00×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATEX
ATEX

Segment breakdown not available.

WGRX
WGRX

Products$1.0M61%
Other$656.6K39%

Related Comparisons